The addition of antibodies targeting human epidermal growth factor 2 receptor (HER2), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor (EGFR) to conventional cytotoxic chemotherapy have resulted in superior outcomes for patients with oesophageal, gastric, and colorectal cancers (CRCs) [21–25]. The gene discussed is ERBB2; the disease is colorectal cancer.